ritonavir

Molecular docking study showed Elbasvir (1) to exhibit the strongest binding affinity (-8.1 kcal/mol), followed by Velpatasvir (2) (-7.6 kcal/mol), Daclatasvir (3) (-7.5 kcal/mol), Ritonavir (4) (-6.2 kcal/mol), Paliperidone Palmitate (5) (-5.9 kcal/mol), Saralasin (6) (-5.4 kcal/mol), Nystatin (8) (-5.2 kcal/mol), and Cobicistat (-5.1 kcal/mol)...Overall, the study provides mechanistic insights into the molecular interactions between FGF2 and these candidate drugs, highlighting the promising potential of compounds 1-6 and 8 for subsequent in vitro validation in cancer therapeutics. The online version contains supplementary material available at 10.1007/s40203-025-00495-2.

P1/2, N=862, Recruiting, DualityBio Inc. | Trial completion date: Jan 2028 --> May 2028 | Trial primary completion date: Sep 2027 --> Dec 2027

P1/2, N=750, Recruiting, DualityBio Inc. | Trial completion date: Sep 2026 --> Jan 2028 | Trial primary completion date: Sep 2026 --> Sep 2027

Finally, consistent with the key role that AKT and EMT play in OSCC radio-resistance, RTV increased OSCC cells' sensitivity to therapeutic doses of ionizing radiation. These preliminary in vitro findings encourage the use of RTV to prevent the malignant evolution of OPMDs, reduce the risk of OSCC metastasis, and improve the outcomes of anti-OSCC radiotherapy.

ALKBH2 overexpression is observed in many cancer and leads to temozolomide resistance in glioblastoma cell lines...Building on our previously reported finding that the HIV protease inhibitor ritonavir selectively binds and inhibits ALKBH2, we synthesized a BODIPY-labeled ritonavir (rit-BD) as an imaging agent...Furthermore, In vitro and in cellulo experiments and live-cell imaging confirmed that rit-BD could be used to label ALKBH2 in the living cell nucleus. Our findings establish rit-BD as a unique dual-purpose agent for visualizing ALKBH2 dynamics and inhibiting DNA repair activity in cancer cells.

While eleven compounds (aldosterone, arecoline, bortezomib, dasatinib, decitabine, dexamethasone, erlotinib, everolimus, gefitinib, temsirolimus, and thalidomide) either had no effect on median lifespan or were toxic, five compounds (all-trans retinoic acid, berberine, fisetin, propranolol, and ritonavir) extended lifespan in Caenorhabditis elegans . Evolutionary conservation of retinoic acid as a signaling ligand and the structure of the downstream effector network of retinoic acid combine to suggest that the all-trans retinoic acid pathway is an ancient metabolic regulatory system that can modulate lifespan. Our results highlight the potential of combining computational prediction of longevity interventions with the power of nematode functional genetics and underscore that the manipulation of a conserved metabolic regulatory circuit by co-opting endogenous signaling molecules is a powerful approach for discovering aging interventions.

P1, N=24, Recruiting, University of Miami | Trial completion date: Jul 2030 --> Apr 2030 | Trial primary completion date: Jul 2029 --> Apr 2029

The cell and mouse models (2-month-old versus 23-month-old) were treated with ritonavir, lopinavir, ethanol, or cocaine derivative hippuric acid. In the aged mice fed alcohol diet and the anti-HIV drugs, hepatic GRP78, CHOP, USP17, PPARγ, and triglycerides, number of senescent or dead hepatocytes, blood levels of alanine aminotransferase were significantly increased and RCE1 was reduced compared to young mice fed alcohol and the drugs. These results suggest that protein factors and responses that potentially function in ameliorating cellular stresses are undermined and protein factors that might cause cell dysfunctions or injury are exacerbated in the senescent hepatocytes and liver of aged mice treated with alcohol and anti-HIV drugs.

P1, N=24, Recruiting, University of Miami | Not yet recruiting --> Recruiting

P1, N=32, Recruiting, Jiangsu HengRui Medicine Co., Ltd. | Not yet recruiting --> Recruiting

P1, N=24, Not yet recruiting, University of Miami | Trial completion date: Mar 2030 --> Jul 2030 | Initiation date: Mar 2025 --> Jul 2025 | Trial primary completion date: Mar 2029 --> Jul 2029

Druggability prediction of these hub protein pockets further identified RBBP4 as the most promising target, with Ritonavir emerging as a potential epidrugs. These findings provide a crucial foundation for future epidrugs discovery targeting cancer.